DRUG · Unmapped registry intervention
HLX10
Find medicine records ·
Find other trials using this name
Clinical trial
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
NCT04033354
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
carboplatin and nab paclitaxel
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Squamous Non Small Cell Lung Cancerunresolved
Interventions
Sponsors & collaborators
Shanghai Henlius Biotechlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04033354 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.